Skip to main content
An official website of the United States government

autologous native ESR1-pulsed DC1 vaccine alternating with autologous mutated ESR1-pulsed DC1 vaccine

A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DC1s) pulsed with either native or mutated estrogen receptor alpha (ERa; estrogen receptor 1; ESR1), with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated to produce DC1s and pulsed with either native or mutated ESR1. Alternating weekly between autologous native ESR1-pulsed and mutated ESR1-pulsed DC1 vaccine, upon administration, the autologous native and/or mutated ESR1-pulsed DC1 vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against ESR1-positive tumor cells, which may result in tumor cell death and decreased tumor growth. ESR1 is overexpressed and/or mutated in certain cancers.
Synonym:autologous DC1s pulsed with native or mutated ESR1
autologous native ESR1-pulsed DC1s/mutated ESR1-pulsed DC1s
Search NCI's Drug Dictionary